Research highlights cutting-edge applications
of AI and behavioral science to automate care and new data on
treatment in overweight patients without obesity
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to
ending obesity, today announced acceptance of five abstracts that
will be presented at Obesity Week 2023, the annual meeting of The
Obesity Society to be held in Dallas, Texas from October 14-17.
Presentations will include new findings on the use of artificial
intelligence (AI) and machine learning to support provider
decision-making and streamline workflow, automate coaching and
follow-up, and assess changes in appetite.
“The science is clear: weight loss treatments must go
hand-in-hand with evidence-based strategies to achieve lifestyle
modification. We are delighted to present our research focused on
AI-powered patient monitoring, digital behavior change coaching,
and digital self-monitoring of changes in appetite," says Dr. Paul
Sacher, Vice President of Behavioral Science for Allurion. "We
believe this data validates the investments we have made in
building out our AI and behavioral science teams and lays the
foundation for future work that leverages generative AI to make
these features conversational to further increase engagement.”
New data from a study on the use of the Allurion Program in
overweight patients without obesity with a BMI of less than 27 will
also be presented.
One of the most effective ways to treat obesity is to prevent it
altogether by intervening when a patient is simply overweight,"
says Dr. Roberta Ienca, one of the study’s co-authors. "This
initial data in patients with a BMI less than 27 opens the door to
further expansion of the Allurion Program, especially given its
favorable safety profile.”
Details of the presentations are as follows:
Title: A Novel Swallowable Gastric Balloon Promotes Safe
Weight Loss in Patients with a BMI less than 27 Presenter:
Roberta Ienca, M.D., Weight Management Center, Nuova Villa Claudia
Clinic Poster: 015
Title: Digital Appetite Tracking Enhances Awareness of
Hunger and Satiety in Procedureless Balloon Patients
Presenter: Paul Sacher, PhD., Allurion Technologies
Poster: 029
Title: Machine Learning to Predict Success of Response
for Patients Treated with a Procedureless Balloon Presenter:
Ben Ainscough, PhD., Allurion Technologies Poster: 265
Title: A Path to Automation: Text-Based Coaching Improves
Well-Being in Procedureless Balloon Patients Presenter: Paul
Sacher, Ph.D., Allurion Technologies Poster: 306
Title: A Path to Automation: Text-Based Coaching Achieves
Key Outcomes in Procedureless Balloon Patients Presenter:
Paul Sacher, Ph.D., Allurion Technologies Poster: 307
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is
a weight-loss platform that combines the Allurion Gastric Balloon,
the world’s first and only swallowable, procedure-less gastric
balloon for weight loss, the Allurion Virtual Care Suite, including
the Allurion Mobile App for consumers, Allurion Insights for
healthcare providers featuring the Iris AI Platform, and the
Allurion Connected Scale and Health Tracker devices. The Allurion
Virtual Care Suite is also available to providers separately from
the Allurion Program to help customize, monitor and manage
weight-loss therapy for patients regardless of their treatment
plan: gastric balloon, surgical, medical or nutritional. The
Allurion Gastric Balloon is an investigational device in the United
States.
For more information about Allurion and the Allurion Virtual
Care Suite, please visit www.allurion.com.
Forward-Looking Statements
This press release may contain certain forward-looking
statements within the meaning of the U.S. federal and state
securities laws. These forward-looking statements generally are
identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions and
include statements regarding Allurion’s expectations for, and
market acceptance of, the Allurion Program. Forward-looking
statements are predictions, projections and other statements about
future events that reflect the current beliefs and assumptions of
Allurion’s management based on information currently available to
them and, as a result, are subject to risks and uncertainties. Many
factors could cause actual future results or developments to differ
materially from the forward-looking statements in this
communication, including but not limited to (i) the ability of
Allurion to obtain regulatory approval for and successfully
commercialize the Allurion Program, (ii) the results of clinical
data from its studies, (iii) the evolution of the markets in which
Allurion competes, (iv) the ability of Allurion to defend its
intellectual property and satisfy regulatory requirements, (v) the
impact of the COVID-19 pandemic on Allurion’s business, (vi)
Allurion’s expectations regarding its market opportunities and
(vii) the risk of economic downturns and a changing regulatory
landscape in the highly competitive industry in which Allurion
operates. The foregoing list of factors is not exhaustive. You
should carefully consider the foregoing factors and the other risks
and uncertainties described in the “Risk Factors” section of the
proxy statement/prospectus contained in Allurion’s Registration
Statement on Form S-4 (333-271862), the company’s Form 8-K filed on
August 7, 2023 (as amended), and other documents filed by Allurion
from time to time with the U.S. Securities and Exchange Commission.
These filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Allurion assumes no obligation and does not intend
to update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Allurion
does not give any assurance that it will achieve its
expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231004073837/en/
US Media Contact Brian Ruby ICR 203-682-8268
brian.ruby@icrinc.com
Global Media Contact Cedric Damour PR Manager +33 7 84 21
02 20 cdamour@allurion.com
Investor Contact Mike Cavanaugh ICR Westwicke
617-877-9641 mike.cavanaugh@westwicke.com
Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Nov 2024 to Dec 2024
Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Dec 2023 to Dec 2024
